Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D M Paton

Showing results (1-10 of 144) with videos related to

Pageof 15
Sort By:
British Medical Journal|August 27, 2010
SERUMTHERAPY BY THE MOUTHD M Paton
The New Zealand Medical Journal|March 26, 1980
Bioavailability of two preparations of frusemideD M Paton
The Journal of Pharmacy and Pharmacology|August 1, 1970
Effects of induced sodium gradients on the transport of metaraminolD M Paton
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|July 21, 1984
Adverse drug reactions in the elderlyD M Paton
The Journal of Pharmacy and Pharmacology|July 1, 1976
Effect of adrenergic neuron blocking agents and biguanides on the efflux of extragranular noradrenaline from adrenergic nerves in rabbit atriaD M Paton
The Journal of Pharmacy and Pharmacology|February 1, 1980
Presynaptic inhibition of neurotransmission in rat vas deferens by 2-(p-methoxyphenyl) adenosine, ethyl adenosine-5'-carboxylate and N-cyclopropyl adenosine-5'-carboxamideD M Paton
Drugs of Today (Barcelona, Spain : 1998)|May 12, 2017
Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitisD M Paton
British Journal of Pharmacology|October 1, 1975
Proceedings: Mechanism of K+-induced release of cytoplasmic noradrenaline from adrenergic nervesD M Paton
Drugs of Today (Barcelona, Spain : 1998)|November 14, 2019
Risankizumab.rzaa: an interleukin monoclonal antibody antagonist binding to the p19 subunit of human IL-23 cytokineD M Paton
Drugs of Today (Barcelona, Spain : 1998)|March 13, 2020
Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's diseaseD M Paton
Pageof 15

Showing results (1-10 of 144) with videos related to

Sort By:
Pageof 15
British Medical Journal|August 27, 2010
SERUMTHERAPY BY THE MOUTHD M Paton
The New Zealand Medical Journal|March 26, 1980
Bioavailability of two preparations of frusemideD M Paton
The Journal of Pharmacy and Pharmacology|August 1, 1970
Effects of induced sodium gradients on the transport of metaraminolD M Paton
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|July 21, 1984
Adverse drug reactions in the elderlyD M Paton
The Journal of Pharmacy and Pharmacology|July 1, 1976
Effect of adrenergic neuron blocking agents and biguanides on the efflux of extragranular noradrenaline from adrenergic nerves in rabbit atriaD M Paton
The Journal of Pharmacy and Pharmacology|February 1, 1980
Presynaptic inhibition of neurotransmission in rat vas deferens by 2-(p-methoxyphenyl) adenosine, ethyl adenosine-5'-carboxylate and N-cyclopropyl adenosine-5'-carboxamideD M Paton
Drugs of Today (Barcelona, Spain : 1998)|May 12, 2017
Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitisD M Paton
British Journal of Pharmacology|October 1, 1975
Proceedings: Mechanism of K+-induced release of cytoplasmic noradrenaline from adrenergic nervesD M Paton
Drugs of Today (Barcelona, Spain : 1998)|November 14, 2019
Risankizumab.rzaa: an interleukin monoclonal antibody antagonist binding to the p19 subunit of human IL-23 cytokineD M Paton
Drugs of Today (Barcelona, Spain : 1998)|March 13, 2020
Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's diseaseD M Paton
Pageof 15